DK0697893T3 - Nervetrådproteingenekspression og detektion af Alzheimers sygdom - Google Patents

Nervetrådproteingenekspression og detektion af Alzheimers sygdom

Info

Publication number
DK0697893T3
DK0697893T3 DK94915396T DK94915396T DK0697893T3 DK 0697893 T3 DK0697893 T3 DK 0697893T3 DK 94915396 T DK94915396 T DK 94915396T DK 94915396 T DK94915396 T DK 94915396T DK 0697893 T3 DK0697893 T3 DK 0697893T3
Authority
DK
Denmark
Prior art keywords
alzheimer
disease
detection
gene expression
protein gene
Prior art date
Application number
DK94915396T
Other languages
Danish (da)
English (en)
Inventor
Jack R Wands
La Monte Suzanne M De
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of DK0697893T3 publication Critical patent/DK0697893T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
DK94915396T 1993-04-20 1994-04-20 Nervetrådproteingenekspression og detektion af Alzheimers sygdom DK0697893T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5055993A 1993-04-20 1993-04-20

Publications (1)

Publication Number Publication Date
DK0697893T3 true DK0697893T3 (da) 2006-02-20

Family

ID=21965952

Family Applications (2)

Application Number Title Priority Date Filing Date
DK94915396T DK0697893T3 (da) 1993-04-20 1994-04-20 Nervetrådproteingenekspression og detektion af Alzheimers sygdom
DK04076254T DK1564293T3 (da) 1993-04-20 1994-04-20 Nervetrådproteingenekspression og detektion af Alzheimers sygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04076254T DK1564293T3 (da) 1993-04-20 1994-04-20 Nervetrådproteingenekspression og detektion af Alzheimers sygdom

Country Status (11)

Country Link
EP (2) EP1564293B9 (de)
JP (2) JP3513859B2 (de)
KR (1) KR100392244B1 (de)
AT (2) ATE312348T1 (de)
CA (1) CA2161097A1 (de)
DE (2) DE69435136D1 (de)
DK (2) DK0697893T3 (de)
ES (2) ES2255054T3 (de)
NZ (1) NZ266072A (de)
PT (1) PT1564293E (de)
WO (1) WO1994023756A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
AU1110297A (en) * 1995-12-12 1997-07-03 Kyowa Hakko Kogyo Co. Ltd. Novel dnas, novel polypeptides and novel antibodies
US5936078A (en) * 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
CA2282729A1 (en) 1997-02-26 1998-09-03 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
US7226730B1 (en) 1997-02-26 2007-06-05 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
EP1006794B1 (de) 1997-03-12 2007-11-28 Robert W. Esmond Verfahren zur behandlung oder prävention der alzheimerischen krankheit
EP1392347B1 (de) 2001-05-16 2005-08-03 Nymox Corporation Prävention des zelltodes durch verwendung der segmente der neurofilamentproteine
EP1541166B1 (de) * 2001-05-16 2007-12-19 Nymox Corporation Prävention des Zelltodes durch Verwendung von Segmenten der Neurofilamentproteinen
US6770797B2 (en) 2001-06-01 2004-08-03 Rhode Island Hospital Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid
EP1714979A3 (de) * 2001-11-16 2007-04-25 Nymox Corporation Peptide für die Behandlung von Tumoren und anderen Zuständen, die das entfernen oder zerstören von Zellen erfordern
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EA200801853A1 (ru) * 2006-02-28 2009-02-27 Наймокс Корпорейшн Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
CN119173632A (zh) * 2022-05-10 2024-12-20 豪夫迈·罗氏有限公司 靶向cfp-elk1基因间区域的反义寡核苷酸
WO2024227045A1 (en) * 2023-04-27 2024-10-31 Siemens Healthcare Diagnostics Inc. High-sensitivity assay for serum neurofilament light chain cross reference to related applications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378924B1 (de) * 1988-12-21 1996-11-13 The General Hospital Corporation Nachweis einer neurologischen Krankheit oder einer Funktionsstörung

Also Published As

Publication number Publication date
AU6666994A (en) 1994-11-08
JPH08509808A (ja) 1996-10-15
ES2312913T3 (es) 2009-03-01
NZ266072A (en) 1997-07-27
JP2004097227A (ja) 2004-04-02
EP1564293B9 (de) 2009-08-19
EP1564293A1 (de) 2005-08-17
KR100392244B1 (ko) 2003-11-28
JP3513859B2 (ja) 2004-03-31
EP0697893B1 (de) 2005-12-07
CA2161097A1 (en) 1994-10-27
DK1564293T3 (da) 2009-01-12
EP1564293B1 (de) 2008-08-27
DE69434844D1 (de) 2006-10-19
ES2255054T3 (es) 2006-06-16
ATE406444T1 (de) 2008-09-15
ATE312348T1 (de) 2005-12-15
AU674581B2 (en) 1997-01-02
PT1564293E (pt) 2008-12-02
EP0697893A4 (de) 1996-12-18
DE69434844T2 (de) 2006-12-14
EP0697893A1 (de) 1996-02-28
WO1994023756A1 (en) 1994-10-27
DE69435136D1 (de) 2008-10-09

Similar Documents

Publication Publication Date Title
DK0697893T3 (da) Nervetrådproteingenekspression og detektion af Alzheimers sygdom
ATE365744T1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
EP0442961A4 (en) Hybrid procoagulant proteins
PT939804E (pt) Neutroquina alfa
SE8106641L (sv) Hybrida humanleukocytinterferoner
DE69434926D1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
DE69735375D1 (de) Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung
EP1009814A4 (de) Kdr, ein menschlicher tyrosin kinase rezeptor
ATE73494T1 (de) Antigene proteine und diese enthaltende impfstoffe zur verhuetung von kokzidiose.
ATE412740T1 (de) Menschliches alpha-endokin
ATE301716T1 (de) Vmp-ähnliche sequenzen von pathogener borrelia
ATE380867T1 (de) Lactoferrinrezeptorgen von moraxella
ATE106454T1 (de) Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen.
DE68928728D1 (de) Diagnose von retinoblastoma
BR9710975A (pt) Genes de proteìna de adesão de superfìcie exposta de 120 kda imunodominante de ehrlichia chaffeensis
EP0876491A4 (de) Ein gen des "langen qt syndroms" (long qt syndrom), welches kvlqt1 kodiert und seine wechselwirkung mit mink
BR9915066A (pt) Processo para identificar proteìnas de expressão traduzidas de uma sequência de nucleotìdeos, proteìna recombinante purificada, sequência de nucleotìdeos, processos de triagem para identificar clones de expressão em uma biblioteca, para triagem de uma biblioteca de sequências de nucleotìdeos, para identificar sequências de genes antigênicos de uma amostra de sequências de nucleotìdeos e para identificar uma sequência de gene antigênica terapêutica, vetor recombinante, célula hospedeira, sequência de aminoácidos, polipeptìdeo isolado e purificado, anticorpo, e, processo para tratar uma infecção
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
DE69634994D1 (de) Bindegewebe-wachstumsfaktor 3.
AU5315790A (en) Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p. falciparum at the sporozoite stage and in the hepatocytes
ATE312914T1 (de) Rdgb-proteine
ATE414772T1 (de) Das hohe knochenmasse gen auf 11q13.3
Schröder et al. Identification of a novel platelet-derived neutrophil-chemotactic polypeptide with structural homology to platelet-factor 4
DE3876227D1 (de) Malaria-spezifische dna-sequenzen, ihre expressionsprodukte und deren verwendung.
EP1085090A4 (de) MIT IgA-NEPHROPATHIE ASSOZIIERTE DNS